An International Publisher for Academic and Scientific Journals
Author Login 
Scholars Journal of Applied Medical Sciences | Volume-7 | Issue 11
Assessment of Serum Paraoxonase and Its Relation with Endothelial Dysfunction in Rheumatoid Arthritis Patients
Dr. Ravi Shankar Prasad, Dr. Rahul Saxena, Dr. Veeru Prakash, Dr. Alok Milton Lal
Published: Nov. 16, 2019 | 73 55
DOI: 10.36347/sjams.2019.v07i11.025
Pages: 3611-3615
Downloads
Abstract
Background: Free radicals mediated various sorts of destructive events along with systemic inflammation overwhelm the protective action of antioxidants and responsible for disease development including rheumatoid arthritis (RA). However, only few studies have been documented to enlighten the biochemical mechanism involved in pathophysiology of RA along with endothelial dysfunction and altered activity of serum paraoxonase. Aim: The present study was carried out to assess serum Paraoxonase (PON), plasma Nitric oxide (NO), marker of lipid peroxidation and systemic inflammation in the blood samples of RA patients and to determine their relation in the development of CVD risk. Material & method: Serum PON, oxidative stress markers (malondialdehyde , MDA), NO and CRP levels were estimated in 30 RA subjects (35-50 years) by using standard methods and statistically compared with 30 age matched healthy controls. Result: Marked depletion in plasma NO level and serum paraoxonase activity (p<0.05) were observed in RA subjects as compared to healthy controls whereas serum CRP and malondialdehyde levels (MDA) were increased significantly (p<0.001) in RA subjects. In addition, serum PON activity was directly correlated with endothelial dysfunction, and inversely related to lipid peroxidation and systemic inflammation. Conclusion: Thus, assessment of serum paraoxonase along with NO in RA patients plays a crucial role for early interpretation of future cardiovascular complications. Therefore, treatment of RA should include not only adoption of antioxidant rich diet along with anti-inflammatory drugs but also monitoring of cardiac markers on regular basis for early prediction and to reduce the burden of CVD risk in RA patients.